# Bremelanotide Dosage — The 1.75 mg FDA-Approved Regimen and Its Pharmacokinetics > Documentation of the FDA-labeled 1.75 mg subcutaneous bremelanotide regimen, the Phase 2b dose-finding rationale, and the pharmacokinetic profile that supports on-demand patient-self-administered dosing. The approved 1.75 mg subcutaneous regimen, its pharmacokinetic basis, and the dose-finding history that selected it. ## DOC.02 // PLAIN BRIEF The FDA-approved bremelanotide dose is one thing: 1.75 mg under the skin, taken as needed about 45 minutes before sex, no more than once a day, and no more than eight times a month. The dose was selected in a Phase 2b trial that compared three doses and chose 1.75 mg as the best balance of effect and tolerability. After injection, peak blood levels arrive in about an hour and the drug clears within a few hours — that window is why on-demand dosing works, and why the small blood-pressure rise it causes is temporary. The approved product is a single-dose autoinjector; it is not the same thing as compounded 'PT-141' vials sold by research-peptide vendors, which have not been evaluated for purity, identity, or stability. The dosage page below documents the regimen, pharmacokinetics, contraindications, and the regulatory distinction between the approved product and compounded preparations. ## The approved regimen The FDA-approved bremelanotide regimen is a single 1.75 mg dose by subcutaneous injection into the abdomen or thigh, taken as needed approximately 45 minutes before anticipated sexual activity [06][10]. The label specifies two upper limits: no more than one dose in any 24-hour period, and no more than eight doses per month [06]. The product is supplied as a single-dose autoinjector designed for patient self-administration after instruction, which is the feature that makes mail-order pharmacy fulfillment from a telehealth prescription operationally workable [10]. The indication is narrow: acquired, generalized HSDD in premenopausal women. It is not approved for postmenopausal women, not approved for men, and not approved for any other indication, including any of the exploratory uses described on the research page [06]. Off-label prescribing is a separate matter under state medical-board standard-of-care rules and is outside the scope of this manual. A clinician who prescribes bremelanotide by telehealth follows the same labeled regimen as a clinician who prescribes it in person. The dispensed product is the same FDA-approved 1.75 mg autoinjector; the dosing instructions are the labeled instructions; the use limits are the labeled limits. ## Pharmacokinetics — why on-demand dosing works Bremelanotide's pharmacokinetic profile is the engineering reason the on-demand regimen is viable. After a single 1.75 mg subcutaneous dose, plasma concentration reaches its peak (Tmax) at approximately 1.0 hour [10]. The terminal half-life is approximately 2.7 hours, with a published range of about 1.9 to 4.0 hours [10]. Absolute subcutaneous bioavailability is approximately 100%, and plasma protein binding is around 21% [10]. Volume of distribution is 25.0 ± 5.8 L; clearance is 6.5 ± 1.0 L/hr [10]. Elimination is roughly 64.8% urinary and 22.8% fecal, with metabolism via hydrolysis of the cyclic peptide amide bond [10]. The cyclic lactam structure — featuring non-standard residues including norleucine and D-phenylalanine — confers resistance to enzymatic degradation relative to linear melanocortin peptides, which is what makes subcutaneous dosing pharmacokinetically robust [10]. The Cmax of approximately 72.8 ng/mL and AUC of approximately 276 hr·ng/mL after a 1.75 mg dose place the on-demand exposure window in roughly a 4-hour onset-to-clearance frame [10] — coincident with the labeled 45-minute pre-activity timing. This profile is also the basis for the labeled blood-pressure precaution: the small, transient post-dose systolic blood-pressure increase observed in ambulatory monitoring peaked within four hours of dosing and resolved within twelve, paralleling the exposure window [05]. ## Dose-finding — why 1.75 mg The 1.75 mg dose was not chosen by guess. A 2019 Phase 2b dose-finding responder analysis evaluated three subcutaneous doses — 0.75 mg, 1.25 mg, and 1.75 mg — in premenopausal women with HSDD or female sexual arousal disorder, and selected 1.75 mg as the dose that best balanced FSFI-D and FSDS-DAO efficacy against the adverse event profile [14]. Earlier Phase 2 work had also evaluated intranasal bremelanotide, which produced a statistically significant increase in moderate-to-high sexual desire versus placebo in premenopausal women with female sexual arousal disorder; that route was abandoned after blood-pressure signals were observed in the intranasal program — a piece of history relevant when patients encounter 'nasal spray PT-141' marketed by unregulated vendors. The 1.75 mg subcutaneous dose then went into the RECONNECT 301 and 302 Phase 3 trials, where both co-primary endpoints reached statistical significance [01], and into the 52-week open-label extension, where the safety and efficacy held across long-term use [02]. The dose has not changed since approval in 2019. ## Use limits, contraindications, and interactions The label imposes specific limits. No more than one dose in 24 hours. No more than eight doses per month [06]. Bremelanotide is contraindicated in uncontrolled hypertension and in known cardiovascular disease, on the basis of the transient post-dose systolic blood-pressure increase observed in ambulatory monitoring [05][06][12]. Co-administration with oral naltrexone is excluded because bremelanotide reduces naltrexone Cmax by approximately 60% and AUC by approximately 40% — a clinically important interaction for patients on naltrexone for alcohol or opioid use disorder [07]. Documented common adverse events at the 1.75 mg dose include nausea (40.0%), flushing (20.3%), headache (11.3%), and injection-site reactions (13.2%) [03]. Nausea accounts for roughly 8% of discontinuations [03]. Focal hyperpigmentation of the face, gums, or breasts was reported in approximately 1% of Phase 3 participants, with risk increasing for darker skin types and frequent dosing; pigmentation may not fully resolve after discontinuation [08]. A telehealth prescriber's medication-reconciliation step is therefore not boilerplate. It is the specific screen the label requires: confirm no oral naltrexone, confirm no monoamine oxidase inhibitor concerns per the label, confirm no uncontrolled hypertension or known cardiovascular disease, confirm patient understanding of the eight-dose monthly limit, and document a counseling step on the hyperpigmentation risk. ## Compounded preparations are not the FDA-approved product Compounded 'PT-141' marketed online is a distinct regulatory category from the FDA-approved bremelanotide product. The approved product is a specific 1.75 mg subcutaneous autoinjector manufactured under FDA oversight and dispensed by licensed pharmacies on receipt of a valid prescription [06][10]. Compounded preparations are made by 503A or 503B pharmacies and have not been evaluated by the FDA for identity, purity, or stability. The FDA has placed PT-141 within its evolving compounding-category framework, which restricts eligibility for compounding under certain conditions [19]. For patients and clinicians, the practical implication is that a 'PT-141' vial purchased from a research-peptide vendor — or a compounded preparation from a pharmacy that has not validated identity and stability for the formulation — is not interchangeable with the FDA-approved product whose pharmacokinetic and safety profile is documented above. The data summarized on this page applies to the FDA-approved 1.75 mg subcutaneous autoinjector. It does not apply to unverified preparations. --- An independent editorial digest of peer-reviewed literature and regulatory documents on the bremelanotide telehealth pathway — not a clinic, not a pharmacy, not medical advice.